• Annovis Bio posted a net loss of USD 17.61 million, or USD 0.63 per share, for first-quarter 2026, widening from a net loss of USD 5.54 million, or USD 0.32 per share, a year earlier.
• Research and development expense more than doubled to USD 16.72 million, while general and administrative expense was little changed at USD 1.29 million.
• Cash and cash equivalents fell to USD 14.22 million as of March 31, 2026, from USD 19.53 million at year-end 2025, excluding gross proceeds from a USD 10 million registered direct offering completed April 10.
• Phase 3 Alzheimer’s trial enrollment reached 85%, with full enrollment targeted in summer 2026; Parkinson’s open-label extension enrollment hit 40%, with full enrollment expected in fourth-quarter 2026.
• Management said it expects first Phase 3 Alzheimer’s top-line results in early 2027, with plans to engage FDA on an NDA for buntanetap as a symptomatic treatment in early 2027 and as a potential disease-modifying treatment in early 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150730PRIMZONEFULLFEED9720966) on May 15, 2026, and is solely responsible for the information contained therein.